

Philip Harvey, PhD
Professor of Psychiatry
University of Miami Miller School of Medicine

COI Disclosures

Dr. Harvey has received consulting fees or travel reimbursements from Alkermes, BMS (Karuna Therapeutics), Boehringer Ingelheim, KyNexis, Minerva Neurosciences, and Neurocrine Biosciences. He has a research grant from Intracellular Therapeutics (now part of Johnson and Johnson) He receives royalties from the Brief Assessment of Cognition in Schizophrenia (Owned by WCG Endpoint Solutions, Inc. and contained in the MCCB). He is chief scientific officer of i-Function, Inc., and Scientific Consultant to EMA Wellness, Inc.